Literature DB >> 30146991

Improving Rural Access to Opioid Treatment Programs.

Quentin Johnson1, Brian Mund1, Paul J Joudrey1.   

Abstract

This article explores challenges to accessing opioid treatment programs in rural areas, and offers solutions that would ease these problems.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30146991      PMCID: PMC9019866          DOI: 10.1177/1073110518782951

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.604


  12 in total

1.  Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences.

Authors:  S Reif; C E Golin; S R Smith
Journal:  AIDS Care       Date:  2005-07

2.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

3.  Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-United States.

Authors:  Karin A Mack; Christopher M Jones; Michael F Ballesteros
Journal:  Am J Transplant       Date:  2017-12       Impact factor: 8.086

4.  Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.

Authors:  Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein
Journal:  Health Aff (Millwood)       Date:  2015-06       Impact factor: 6.301

5.  Geographic access to health care for rural Medicare beneficiaries.

Authors:  Leighton Chan; L Gary Hart; David C Goodman
Journal:  J Rural Health       Date:  2006       Impact factor: 4.333

6.  Buprenorphine MAT as an Imperfect Fix.

Authors:  Brian Mund; Kate Stith
Journal:  J Law Med Ethics       Date:  2018-06       Impact factor: 1.718

Review 7.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Authors:  Bohdan Nosyk; M Douglas Anglin; Suzanne Brissette; Thomas Kerr; David C Marsh; Bruce R Schackman; Evan Wood; Julio S G Montaner
Journal:  Health Aff (Millwood)       Date:  2013-08       Impact factor: 6.301

9.  Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Authors:  Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Tamara Y Boney; Randall A Hoskinson; Donna Wilson; Ryan McDonald; John Rotrosen; Marc N Gourevitch; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; James W Cornish; Sean M Murphy; Charles P O'Brien
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

10.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.

Authors:  Richard P Mattick; Robert Ali; Jason M White; Susannah O'Brien; Seija Wolk; Cath Danz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  3 in total

1.  COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.

Authors:  Ximena A Levander; Jarratt D Pytell; Kenneth B Stoller; P Todd Korthuis; Geetanjali Chander
Journal:  Subst Abus       Date:  2021-10-19       Impact factor: 3.716

2.  Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.

Authors:  Ximena A Levander; Kim A Hoffman; John W McIlveen; Dennis McCarty; Javier Ponce Terashima; P Todd Korthuis
Journal:  Addict Sci Clin Pract       Date:  2021-12-11

Review 3.  Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.

Authors:  Em M Pijl; Abeer Alraja; Elsie Duff; Carol Cooke; Stephen Dash; Nichole Nayak; Jesse Lamoureux; Ginette Poulin; Erin Knight; Ben Fry
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.